GSK Loses Bid To End 53 Zofran Birth Defects Cases
By Chris Villani · October 24, 2019, 5:44 PM EDT
GlaxoSmithKline has largely lost its bid to end 58 cases in a consolidated suit claiming its anti-nausea medication Zofran caused birth defects when taken by pregnant women, as a Massachusetts federal judge...
To view the full article, register now.